Trial Profile
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (RELEVANT)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Oct 2015
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- Acronyms RELEVANT
- Sponsors Roche
- 19 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Mar 2014 Planned End Date changed from 1 Dec 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.
- 18 Sep 2013 Planned end date changed from 1 Jun 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.